May 8, 2017 / 11:18 AM / in 7 months

BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin

May 8 (Reuters) - Oncolytics Biotech Inc:

* Oncolytics Biotech Inc announces FDA fast track designation for Reolysin in metastatic breast cancer

* Oncolytics Biotech-based on co’s understanding of Reolysin, is pursuing metastatic breast cancer as its primary focus for late-stage clinical testing Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below